Tibulizumab

Last updated March 07, 2019

Tibulizumab
Monoclonal antibody
Type	?
Source	Humanized
Target	BAFF
Clinical data
Synonyms	LY 3090106
ATC code	none
Identifiers
CAS Number	1849636-24-3
ChemSpider	none
UNII	42HQ15W1ZF
Chemical and physical data
Formula	C₈₉₃₄H₁₃₆₉₈N₂₃₉₈O₂₈₀₈S₅₆
Molar mass	201.4 g/mol

Tibulizumab (LY 3090106) (INN ^[1]) is a humanized monoclonal antibody designed for the treatment of autoimmune diseases.

This drug was developed by Eli Lilly and Co.^[2]

References

↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Tibulizumab, American Medical Association.

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	Immunosuppression : Abrilumab Adalimumab Anifrolumab ^† Atorolimumab Avelumab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab ^† Fresolimumab Gimsilumab Golimumab Lanadelumab Lenzilumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Sarilumab Sifalimumab Tabalumab Tezepelumab ^† Ulocuplumab Varlilumab Immune activation: Ipilimumab Atezolizumab Durvalumab Nivolumab Pembrolizumab Tremelimumab ^† Urelumab Other: Bertilimumab Zanolimumab
Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric ("-lixi-")	Andecaliximab ^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized ("-lizu-")	Immunosuppressive: Aselizumab Apolizumab ^§ Benralizumab Cedelizumab Certolizumab pegol Crizanlizumab ^† Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab ^† Fontolizumab Inebilizumab ^† Itolizumab Lampalizumab ^† Letolizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140 ^† Quilizumab Ravulizumab ^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Samalizumab Siplizumab Talizumab Teplizumab Tibulizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412 ^§ Non-immunosuppressive: Ibalizumab
Chimeric + humanized ("-lixizu-")	Otelixizumab Tavolimab
Veterinary ("-lvet-")	Gilvetmab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab ^† Ustekinumab
Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Clazakizumab Enokizumab Gevokizumab Ixekizumab Mirikizumab Lebrikizumab Olokizumab ^† Perakizumab Risankizumab ^† Tildrakizumab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab ^‡ Lemalesomab Sulesomab

^# WHO-EM
^‡ Withdrawn from market
Clinical trials:
- ^† Phase III
- ^§Never to phase III

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.